Getting drugs into the brain: 43 CNS delivery companies, scored

About this analysis

AcademicLabs maps the research and innovation landscape for life science teams. The platform indexes over 116 million publications, 33 million patents, 23 million researcher profiles, 150,000 research groups, 1.1 million clinical trials and 629,000 companies, and connects them so that a single question can be answered across all of that evidence at once.

This report is the output of one such question. A single structured search for brain and CNS delivery technologies, restricted to therapeutic biotech companies holding patents published between January 2021 and December 2026, returned 43 companies. Each company was then evaluated independently against the same nine-criterion framework, using its own recent patents, publications, website, news, grants and clinical trials on the topic. The individual evaluations were then composed into the landscape below.

Every company name in this report links to its AcademicLabs profile, so any claim can be traced back to the underlying evidence in one click. The search query, filters and scoring framework are in the Method section, and every company's nine scores with their reasoning open from the report.

Executive Summary

The objective was to identify targeted brain and CNS delivery companies suitable for in-licensing, co-development or acquisition by pharmaceutical companies. Across the 43 evaluated profiles, the strongest evidence currently favours direct-CSF or intracranial delivery, while genuinely systemic, targeted BBB crossing remains a high-value but predominantly preclinical opportunity.

The leading near-term platform is Alnylam Pharmaceuticals’ intrathecal C16-siRNA franchise, supported by human CNS pharmacodynamics, multiple Phase 1-2 programs and commercial RNAi infrastructure. AskBio provides the most mature integrated AAV-neurosurgical delivery stack, with MRI-confirmed putaminal coverage and a Phase 2 Parkinson’s program. Both are best approached through target- or indication-specific collaboration because of their scale or existing strategic ownership.

Among transaction-accessible emerging companies, Aruna Biomedical is the strongest co-development or acquisition candidate. Its neural EV product AB126 has multispecies stroke efficacy, reported IND clearance and engineered-cargo optionality, although GMP comparability and human biodistribution remain critical unknowns. Ossianix is the preferred receptor-mediated BBB-shuttle opportunity: its TfR1 VNARs have delivered functional antibody cargo in rodents, but NHP translation and immunogenicity must be established. Biorchestra offers a strategically important IV RNA-delivery proposition with rodent and company-reported NHP evidence; a milestone-based option is preferable until raw data, repeat-dose toxicology and IND status are verified.

Sangamo Therapeutics’ systemic BBB-penetrant AAV and PRNP-repressor program provides the most compelling brain-wide NHP pharmacology in the set. Its Chapter 11 asset-sale process makes this a time-sensitive asset-acquisition question rather than a routine partnership. In brain oncology, EnGeneIC warrants payload-specific co-development based on clinical delivery experience, active recurrent-GBM development and broad cargo capacity, while recognising that it exploits disrupted tumour vasculature rather than an intact BBB.

Principal risks across the landscape are false-positive brain exposure, species-dependent receptor biology, insufficient cell-type targeting or endosomal escape, peripheral organ uptake, repeat-dose immunogenicity, AAV irreversibility, invasive administration, complex CMC and crowded IP. Patent grants and trial initiation should not be treated as evidence of functional CNS delivery or efficacy.

At a Glance

The bottom line. The strongest evidence in targeted CNS delivery today sits with technologies that bypass the blood-brain barrier rather than cross it. Intrathecal, intracisternal and image-guided intraparenchymal delivery already have human pharmacodynamic and imaging data. Genuinely systemic, targeted BBB crossing remains the higher-value prize, but it is still predominantly preclinical, and only a minority of platforms connect quantitative brain exposure to a functional payload effect.

That gap is the opportunity. Three platforms stand out because they combine real CNS targeting with functional evidence and remain transaction-accessible: Aruna Biomedical, Ossianix and Biorchestra. One more, Sangamo Therapeutics, has the single most compelling systemic dataset in the landscape and is in a Chapter 11 sale process, which makes it a time-boxed question rather than a routine partnership.

Top 10 ranked opportunities

Before any ranking makes sense, it helps to fix the mental model. Every company in this landscape is solving the same problem, but they are not solving it the same way, and the difference decides what evidence should count.

Shuttles, vesicles and synthetic carriers cross the blood-brain barrier. Viral vectors do both: engineered capsids cross it after intravenous dosing, while other programs inject straight into the CSF or brain. Anatomical bypass goes around the barrier with a port or a cannula, and the last group opens a local window with ultrasound or light, or exploits the fact that tumour vessels already leak. That distinction matters more than any score in this report, because a brain signal obtained after intracisternal injection and a brain signal obtained after intravenous dosing are not the same claim, and they should never be compared as if they were.

Quadrants split at a score of 7 on CNS / BBB relevance (vertical) and delivery, biodistribution and functional evidence (horizontal).

Method. Each company was scored from 1 to 10 against nine weighted criteria: CNS/BBB relevance and targeting specificity (18%), delivery, biodistribution and functional evidence (16%), TRL and clinical maturity (13%), payload versatility (9%), differentiation (9%), IP and FTO indicators (8%), CMC and scalability (8%), safety and translatability (9%), and strategic fit (10%). Overall attractiveness is the weighted sum, rounded to one decimal. Ties were resolved by CNS relevance, then evidence quality, then strategic fit. Scores reflect the public evidence in the AcademicLabs record, not undisclosed data or company assertions. The full scoring legend is in the Method section.

The evidence map plots the two heaviest-weighted criteria against each other, which is the fastest way to see where the landscape actually stands. The upper-right region contains companies that combine genuine CNS targeting with delivery evidence. The upper-left region contains companies aimed at the right problem whose evidence is still patent-stage or in-vitro, and it is crowded.

CNS = CNS/BBB relevance and targeting (18%); Evid = delivery, biodistribution and functional evidence (16%); TRL = technology readiness and clinical maturity (13%); Pay = payload versatility (9%); Diff = differentiation (9%); IP = IP and FTO indicators (8%); CMC = CMC and scalability (8%); Safe = safety and translatability (9%); Fit = strategic fit (10%).

Tiering

Companies fall into four bands. The band determines the type of engagement, not the level of scientific interest: several Tier 3 companies are scientifically distinctive but cannot yet be evaluated on evidence.

Tier 1 - Priority (overall 8.4 and above; 7 companies)

Asklepios BioPharmaceutical (AskBio) (8.9), AC Immune (8.8), Alnylam Pharmaceuticals (8.7), Sangamo Therapeutics (8.5), Ossianix (8.5), Aruna Biomedical (8.5), Biorchestra (8.4)

Tier 2 - Active diligence (overall 7.5 to 8.3; 11 companies)

Alcyone Therapeutics (8.3), EnGeneIC (8.2), Prevail Therapeutics (8.1), Blaze Bioscience (8.1), ILIAS Biologics (8.0), Gate2Brain (7.8), REGENXBIO (7.8), TechnoPhage (7.6), Ovid Therapeutics (7.6), IMGT (7.5), AGS Therapeutics (7.5)

Tier 3 - Option value / watch (overall 6.5 to 7.4; 13 companies)

Nano Targeting & Therapy Biopharma (7.4), Codiak Biosciences (7.4), Nanoscope Technologies (7.4), SynerGene Therapeutics (7.4), Neurimmune Holding (7.4), Lauren Sciences (7.3), Ophidion (7.2), VectorY (6.8), ExoStemTech (6.8), Nibec (6.7), Nano Carry (6.5), QurCan Therapeutics (6.5), Seasun Therapeutics (6.5)

Tier 4 - Monitor or decline (overall below 6.5; 12 companies)

ICB International (6.2), Mononuclear Therapeutics (6.2), Pharmacoidea (6.0), Zitra Medicines (5.9), AVROBIO (5.9), Stallergenes Greer (5.8), Harbour Antibodies (5.7), Angiocrine Bioscience (5.7), Neuronity Therapeutics (5.2), Silo Pharma (5.2), Nanoligent (5.2), NanoSphere Health Sciences (4.2)

The score heat map shows how each company earns its overall score. It is worth reading across rows rather than down columns: a high overall score built on CMC and IP with a weak evidence column is a very different proposition from one built on evidence and CNS relevance.

Two patterns are visible immediately. First, IP and differentiation scores are high almost everywhere (averages 8.0 and 8.2), which means they discriminate poorly between candidates at this stage. Second, the evidence, CNS relevance and TRL columns are where the real spread sits, and they are the columns that diligence can actually move.

The reasoning behind the three criteria that most often decide a transaction, for every company. The scores for all nine criteria are in the ranking table above.

AskBio - MRI-guided AAV/CED and CNS vector engineering

Company and technology. Bayer-owned AskBio integrates AAV capsids, promoters, manufacturing and MRI-guided intraputaminal convection-enhanced delivery. AB-1005 delivers AAV2-GDNF to the putamen in Parkinson’s disease.

TRL and evidence. AB-1005 is in a randomised Phase 2 study. Phase 1b delivery achieved approximately 63% mean putaminal coverage and was well tolerated at 18 months (study); serial MRI found no parenchymal toxicity over follow-up extending to five years (long-term study). Clinical efficacy remains unconfirmed.

Differentiation, IP and CMC. The integrated vector-device-imaging stack and prescriptive infusion algorithms are differentiated. Viralgen and Pro10 provide strong manufacturing infrastructure. Emerging BBB-crossing capsids remain preclinical.

Risks and applications. Neurosurgical complexity, variable regional coverage, reflux, off-target dispersion, permanent expression and AAV immunogenicity constrain broad use. The approach is best for focal circuitry and one-time therapies where surgery is justified.

Verdict - co-develop selectively, otherwise benchmark and monitor. AskBio is already strategically owned. Indication-specific collaboration makes sense only for programs that require regional brain delivery.

AC Immune - brain-penetrant Morphomers, CNS vaccines, PET tracers and vectorized antibodies

Company and technology. AC Immune combines brain-penetrant small-molecule Morphomers, CNS vaccines, PET tracers, morADCs and vectorized antibodies against neurodegeneration targets. It is not primarily a carrier-platform company, which is why it sits with the adjacent profiles despite its overall score.

TRL and evidence. Several programs are in Phase 1-2, supported by human CSF antibody data, PET proof-of-concept and clinical immunogenicity (VacSYn). Human tolerability data are available; disease modification remains unproven.

Differentiation, IP and CMC. An unusually integrated precision-neurodegeneration stack across therapeutics and diagnostics, with a broad platform and product estate (freedom to operate remains product-specific) and established clinical-development and partnership infrastructure.

Applications. Its PET portfolio is an example of the integrated measurement this landscape identifies as valuable for delivery development.

Verdict - multi-asset partnering and diagnostic enablement. An attractive multi-asset partnering and diagnostic-enablement opportunity, more relevant for its assets and imaging capabilities than as a delivery platform.

Alnylam Pharmaceuticals - CNS C16-siRNA conjugates

Company and technology. Alnylam Pharmaceuticals is the clinically validated RNAi leader. Its CNS platform uses intrathecal C16-lipid-conjugated siRNAs rather than systemic BBB transport. Payloads include APP, HTT, tau and other genetically defined targets.

TRL and evidence. The platform spans Phase 1-2. Mivelsiran produced robust, durable, dose-dependent CSF sAPPβ reduction with encouraging reported tolerability (Phase 1); ALN-HTT02 is in Phase 1, and MAPT lowering has been demonstrated in NHP brain tissue (NHP study). Evidence quality is high for pharmacodynamics, although clinical disease modification and cell-specific parenchymal distribution remain unproven.

Differentiation, IP and CMC. Differentiation rests on clinically established RNAi chemistry, long duration and a broad target engine. The company has deep conjugate, chemical-modification and LNP IP plus commercial-scale manufacturing.

Risks and applications. Repeat lumbar puncture, CSF-to-parenchyma gradients, long-term CNS safety and target-specific biology are the principal risks. The platform suits neurodegeneration and genetically defined diseases where partial, durable knockdown is desirable.

Verdict - targeted co-development or target-level in-license. A corporate acquisition is impractical and unnecessary. Prioritise target-specific collaboration, regional rights or combination-development arrangements.

Sangamo Therapeutics - systemic BBB AAV plus zinc-finger repression

Company and technology. Sangamo Therapeutics combines engineered, liver-detargeted BBB-penetrant AAV capsids with zinc-finger transcriptional repressors. ST-506 targets PRNP for prion disease.

TRL and evidence. ST-506 is advanced preclinical. A single IV dose generated expression and PRNP repression across all 35 assessed NHP brain regions, while mouse studies showed durable PrP reduction and major survival extension (publication). This is the strongest systemic AAV CNS dataset in the evaluated group, although human safety data are absent.

Differentiation, IP and CMC. The integrated capsid-plus-epigenetic-regulator architecture is unusually differentiated and supported by receptor-informed capsid and zinc-finger IP. Sangamo Therapeutics also possesses meaningful AAV process expertise.

Risks and applications. One-time systemic AAV dosing, immunogenicity, off-target transduction, long-duration gene repression and inability to redose create material risk. Prion disease provides strong mechanistic and orphan-development logic; tau and other dominant toxic proteins are logical extensions.

Transaction constraint. The June 2026 Chapter 11 process and stalking-horse arrangements may determine ownership and freedom to transact (source).

Verdict - immediate asset-acquisition diligence. If legally available, prioritise acquisition or consortium participation for the BBB capsid estate and ST-506. Do not rely on a conventional future partnering process.

Ossianix - VNAR BBB shuttles

Company and technology. Ossianix develops compact shark VNAR domains against TfR1 and CD98hc for systemic receptor-mediated delivery of antibodies and conjugated payloads.

TRL and evidence. The platform is preclinical, approximately TRL 3 to 5. TXB2 delivered functional neurotensin to mouse brain, while TXB4 increased TrkB-antibody brain exposure 12-fold and completely prevented dopaminergic-neuron loss in a mouse Parkinson’s model (study). Anti-CD20 bispecifics achieved 2 to 5% mouse brain:plasma ratios versus 0.25% for unmodified rituximab (abstract). NHP pharmacology is the major missing bridge.

Differentiation, IP and CMC. VNARs are small, stable and compatible with multispecific or site-specific conjugate formats. Granted patents cover TfR binders, transcytosis selection and deimmunised scaffolds. Antibody-like manufacture is feasible, although each fusion will require individual developability work.

Risks and applications. Risks include shark-domain immunogenicity, altered TfR biology, peripheral sinks, affinity-dependent endothelial trapping and species-specific transport. Best applications are high-value antibodies, enzymes and selected oligonucleotide conjugates.

Verdict - platform in-license with payload-specific co-development. Start with one antibody and one enzyme payload, contingent on NHP brain exposure, capillary depletion and safety comparisons against established TfR shuttles.

Aruna Biomedical - AB126 neural EV platform

Company and technology. Aruna Biomedical produces neural stem and progenitor-cell-derived EVs with intrinsic anti-inflammatory and neuroprotective activity. The platform can also carry small molecules, antibodies, peptides and nucleic acids.

TRL and evidence. AB126 has reported FDA IND clearance for acute ischemic stroke and is positioned for Phase 1b/2a entry (2026 abstract). Rat and porcine stroke studies demonstrate lesion, functional and biomarker effects, with large-animal evidence materially improving confidence. Engineered neural EVs increased doxorubicin BBB penetration versus free drug in vivo (study). Much of the recent evidence is company-authored, and human delivery remains untested.

Differentiation, IP and CMC. Neural origin may confer relevant tropism, while native therapeutic activity permits development as both drug and carrier. IP covers neural EV therapy, antibody loading and BBB-enhancing agents. Lyophilisation retained key characteristics and immunomodulatory activity (CMC study), but release specifications and GMP comparability require diligence.

Risks and applications. Key risks are product heterogeneity, mechanism attribution, potency-assay selection, immunogenicity, repeat-dose PK and scalable source-cell manufacturing. Stroke is the most mature indication; TBI, hypoxic injury and engineered-cargo delivery offer expansion.

Verdict - co-develop now, with an acquisition option. Structure a staged agreement around AB126 stroke development and one engineered-cargo program, including option-to-acquire rights after Phase 1 biodistribution, safety and biomarker readouts.

Biorchestra - IV receptor-targeted RNA micelles

Company and technology. Biorchestra’s BTRiN platform uses targeted cationic micelles to deliver ASO or siRNA after IV administration, with reported uptake into neurons, astrocytes and microglia. BMD-001 targets miR-485-3p in Alzheimer’s disease.

TRL and evidence. The program is advanced preclinical, approximately TRL 4 to 5. The target has peer-reviewed mouse evidence showing reductions in amyloid, tau, neuroinflammation and cognitive decline (publication). Brain distribution and knockdown in NHPs are company-reported (update); an expected 2024 IND-enabling milestone was not confirmed in the record.

Differentiation, IP and CMC. Systemic delivery of RNA to multiple brain cell types would be highly differentiated relative to intrathecal oligonucleotides. European micellar IP has been granted. CMC questions include micelle composition, particle-size control, ligand density, encapsulation, stability and batch comparability.

Risks and applications. Repeat-dose cationic-carrier safety, complement activation, liver uptake, endosomal escape and human receptor translation are central risks. Alzheimer’s disease has the strongest evidence; expansion should await platform validation.

Verdict - diligence for co-development, do not acquire yet. Require raw NHP data, independent replication, IND status and repeat-dose toxicology before a major transaction. A milestone-based option agreement is preferred.

EnGeneIC - targeted EDV nanocells for brain oncology

Company and technology. EnGeneIC’s approximately 400-nm bacterial EDV nanocells package cytotoxics, nucleic acids and immune agonists, and use bispecific ligands for EGFR targeting. In GBM, delivery is expected to exploit abnormal tumour vasculature rather than cross an intact BBB.

TRL and evidence. The platform is in Phase I/II oncology development. A prior recurrent-GBM Phase I established human exposure, and a new recurrent-GBM study began dosing in 2026. EGFR-targeted miR-34a EDVs enhanced temozolomide sensitivity in orthotopic patient-derived GBM xenografts (study). Pediatric CNS and solid-tumour treatment was tolerated without dose-limiting toxicity in nine patients, but all progressed (publication).

Differentiation, IP and CMC. EDVs offer unusually broad payload capacity and combine cytotoxic delivery with immune stimulation. The company has clinical-grade production and broad minicell IP, although bacterial-component consistency and immunostimulatory potency require close control.

Risks and applications. Efficacy remains unproven, particle size may limit penetration beyond leaky tumour regions, and EGFR heterogeneity may reduce targeting. The best fit is recurrent GBM and other receptor-positive brain tumours, not neurodegeneration.

Verdict - co-develop in brain oncology. Pursue a payload-specific clinical collaboration with translational biopsies, imaging and immune biomarkers. Defer acquisition until objective response and durability are demonstrated.

Evidence is concentrated in BBB bypass rather than systemic crossing

The strongest human evidence comes from intrathecal, intracisternal or intraparenchymal administration: Alnylam Pharmaceuticals, AskBio, Prevail Therapeutics, REGENXBIO and Alcyone Therapeutics. By contrast, most systemic BBB platforms remain preclinical. This creates a strategic mismatch between the industry’s desired product profile, which is non-invasive systemic administration, and the evidence base actually supporting current development decisions.

Functional evidence is much rarer than brain-associated exposure

Only a minority of platforms connect quantitative delivery to payload function. Strong examples include Sangamo Therapeutics’ NHP PRNP repression, Ossianix’s neuroprotection, Alnylam Pharmaceuticals’ human CSF pharmacodynamics, Aruna Biomedical’s multispecies stroke outcomes and Biorchestra’s reported knockdown. Many patent-led companies do not yet demonstrate capillary-depleted parenchymal exposure, cell specificity or pharmacodynamic activity.

RNA and protein payloads dominate the highest-value opportunity set

RNA therapeutics are represented by Alnylam Pharmaceuticals, Biorchestra, Gate2Brain extensions, Nibec, Seasun Therapeutics, Zitra Medicines and QurCan Therapeutics. Protein and antibody delivery is represented by Ossianix, ILIAS Biologics, Aruna Biomedical, VectorY and AC Immune. These modalities address otherwise inaccessible targets but require intracellular release or controlled expression. A platform that reproducibly delivers RNA to both neurons and glia after systemic dosing remains a major white space.

Transport-receptor diversification is emerging

TfR remains dominant, creating competitive and FTO crowding. Alternative receptors and pathways include CD98hc, lynx1 and nicotinic receptors, SDC3, SLC7A1, LDLR, glucose transporters and other amino-acid-transport systems. The opportunity is not simply to identify another binding target, but to find receptors with high human BBB expression, low peripheral sink, productive abluminal trafficking and tolerance of repeat dosing.

Cell-type targeting is underdeveloped

Most platforms aim for whole-brain exposure without demonstrating delivery to the disease-relevant cell. Exceptions include Neuronity Therapeutics’ microglia concept, ILIAS Biologics’ microglial activity, Biorchestra’s multi-cell claim and AskBio’s regional neuronal delivery. White-space priorities include selective delivery to microglia, astrocytes, oligodendrocytes, inhibitory neurons and disease-associated vascular cells.

CMC is becoming a primary competitive discriminator

EV, AAV and complex nanoparticle companies increasingly recognise that manufacturing is not a downstream task. Aruna Biomedical’s lyophilisation, ILIAS Biologics’ GMP-grade analytics, AGS Therapeutics’ planned GMP infrastructure, ExoStemTech’s TFF processes, AskBio’s Viralgen capacity and Alcyone Therapeutics’ device standardisation illustrate this shift. Platforms with comparable biology will separate on potency assays, stability, batch reproducibility and cost of goods.

Brain oncology is a distinct segment

EnGeneIC, Gate2Brain, Blaze Bioscience, Nano Targeting & Therapy Biopharma and IMGT address brain tumours, but their access mechanisms differ. Tumour-vessel permeability, surgical exposure or focal BBB opening should not be extrapolated to intact-BBB neurodegeneration. Conversely, brain oncology offers faster translational opportunities through resection tissue, imaging and short pharmacodynamic windows.

Precision diagnostics can improve delivery development

AC Immune’s PET portfolio, Biorchestra’s salivary biomarker, Alcyone Therapeutics’ distribution modelling and AskBio’s real-time imaging demonstrate the value of integrated measurement. A major white space is the development of companion imaging or fluid biomarkers that directly quantify CNS delivery, payload activity and target-cell engagement early in humans.

Transaction availability does not track scientific quality

Several scientifically attractive technologies are constrained by ownership or restructuring. AskBio, Prevail Therapeutics and Alcyone Therapeutics are already owned by Bayer, Lilly and Biogen respectively. Sangamo Therapeutics’ assets are in a sale process, while Codiak Biosciences’ technology is legacy IP after bankruptcy. A successful strategy must distinguish technical rank from practical accessibility.

Scientific and translational risks

• False-positive brain delivery: vascular contamination, endothelial sequestration and meningeal or CSF signal can overstate parenchymal exposure.
• Species differences: receptor expression, affinity and trafficking can differ materially between rodents, NHPs and humans.
• Cellular delivery: tissue entry does not establish uptake by the relevant neurons or glia.
• Endosomal escape: particularly important for RNA, proteins and gene editors. Uptake without cytosolic release may be pharmacologically ineffective.
• Payload dependence: a shuttle validated with a small peptide may not carry an antibody, enzyme or oligonucleotide with equivalent efficiency.
• Disease-state dependence: BBB disruption in tumours, stroke or inflammation can inflate apparent performance relative to chronic neurodegeneration.

Clinical and safety risks

Systemic carriers may produce liver, spleen, hematologic or immune toxicity before reaching efficacious brain levels. Receptor-targeted agents can perturb endogenous transport biology. EVs may trigger innate immunity or have poorly defined active components. Cationic nanoparticles may activate complement, and inorganic carriers may persist. Intrathecal devices introduce infection, obstruction and procedure risks; intracranial CED introduces hemorrhage, reflux and distribution variability.

AAV risks include immunogenicity, inability to redose, permanent expression, off-target transduction and long-latency adverse findings. REGENXBIO’s CNS holds illustrate the importance of long-term surveillance and causal investigation. Active immunotherapies and aggregate-clearing antibodies also require monitoring for neuroinflammation and amyloid-related imaging abnormalities.

CMC and manufacturing constraints

Complex products require orthogonal characterisation of identity, size, charge, aggregation, encapsulation, potency, impurities and stability. EV dose units and potency assays remain incompletely standardised. AAV faces capsid-ratio, genome-integrity and high-dose capacity constraints. Multifunctional nanoparticles must control ligand density and payload release across scale. Device-drug combinations add human-factors, sterility and combination-product requirements.

Comparability after process changes is a major risk, because small changes may alter biodistribution. A credible partner should possess a quality-by-design strategy, scalable unit operations, reference standards and a potency assay linked to the proposed mechanism.

Regulatory constraints

Regulators will require platform claims to be substantiated product by product. Novel BBB receptors, EV sources, bacterial particles and triggered BBB-opening technologies may require expanded biodistribution, immunotoxicology and long-term follow-up. Pediatric brain-tumour or neurogenetic programs face additional ethical and procedural requirements. Regulatory designations and orphan status can accelerate dialogue but do not reduce the need for delivery-specific evidence.

IP and competitive risks

TfR shuttle, AAV capsid, LNP and EV fields are crowded. Patent grants may be narrow, overlapping or dependent on particular sequences, formats and uses. Platform breadth can be less valuable than defensible claims around the clinically selected construct. Diligence must address ownership, inventorship, academic licenses, prosecution status, enablement, sequence overlap, receptor-use claims and rights to payload-carrier combinations.

Commercial constraints

CNS delivery must create enough therapeutic benefit to justify added cost and complexity. Surgical or chronic-device routes are best suited to severe disease, durable therapy or infrequent dosing. Systemic platforms must achieve commercially practical doses and repeat-dose safety. Broad neurodegeneration indications require scalable administration and strong payer-relevant outcomes; rare diseases can tolerate greater procedure burden but offer smaller markets.

Where the opportunity sits

Three opportunities follow from the constraints above. First, the company that reproducibly delivers RNA to both neurons and glia after intravenous dosing would define the category, and no one in this set has yet proven it. Second, cell-type-selective delivery is underdeveloped: only a few companies show delivery to the disease-relevant cell. Third, companion imaging or fluid biomarkers that quantify delivery, payload activity and target-cell engagement early in humans remain a major white space.

A three-horizon portfolio, not a single platform bet

No single modality is optimal across all payloads and diseases. The strongest position combines three horizons rather than one universal platform.

Horizon 1 - clinically validated direct-CNS delivery

• Pursue target-level partnerships with Alnylam Pharmaceuticals for intrathecal RNAi programs where the disease biology is strong.
• Use AskBio as a co-development benchmark or partner for focal, one-time AAV programs requiring image-guided CED.
• Develop route-selection capabilities covering lumbar intrathecal, intracisternal and intraparenchymal delivery, including CSF modelling and imaging.

Horizon 2 - high-priority systemic enabling platforms

• Ossianix: negotiate a platform evaluation and payload-specific license. Require NHP studies before exercising broader rights.
• Aruna Biomedical: pursue co-development of AB126 and one engineered-cargo program, with an option to acquire after early clinical validation.
• Biorchestra: enter confidential diligence and consider a milestone-based option agreement only after verification of NHP and IND-enabling data.
• Sangamo Therapeutics: initiate immediate legal and asset diligence for BBB capsids and ST-506, because the restructuring process creates a time-sensitive opportunity.

Horizon 3 - option-value technologies

• Evaluate AGS Therapeutics nose-to-brain microalgal EVs, ILIAS Biologics protein-loaded exosomes, TechnoPhage sdAb-liposomes, Gate2Brain MiniAp4, IMGT focused ultrasound and Lauren Sciences V-Smart through paid research collaborations with predefined stop/go criteria.
• Maintain a standardised screening funnel for QurCan Therapeutics, Zitra Medicines, Seasun Therapeutics, Nibec, Nano Carry and Pharmacoidea. Do not execute broad licenses on the basis of patent claims alone.

Brain-oncology strategy

Prioritise EnGeneIC co-development for recurrent GBM or another EGFR-positive CNS tumour, using paired blood, imaging, CSF and resection-tissue analyses. Consider Gate2Brain as a pediatric-oncology option, contingent on independent confirmation of the reported brain-transport advantage and completion of IND-enabling CMC. Blaze Bioscience is best assessed as a surgical-imaging or drug-device opportunity, not as a mature therapeutic BBB platform.

Transaction pathways

• Platform evaluation plus option: preferred for Ossianix, Biorchestra, AGS Therapeutics, TechnoPhage and early nanocarriers.
• Co-development with acquisition option: preferred for Aruna Biomedical and potentially Gate2Brain.
• Asset acquisition: preferred for available Sangamo Therapeutics BBB capsid and ST-506 assets, and potentially selected Codiak Biosciences legacy IP.
• Clinical collaboration: preferred for EnGeneIC and Alnylam Pharmaceuticals target programs.
• Monitor or decline: monitor ICB International, Zitra Medicines, Pharmacoidea, Harbour Antibodies, Neuronity Therapeutics and Silo Pharma pending functional evidence. Decline CNS-focused investment in Stallergenes Greer, NanoSphere Health Sciences and Nanoligent, because strategic fit is insufficient.

Diligence questions that separate real delivery from a brain signal

Biology and delivery

• What is the absolute unbound brain concentration and brain:plasma ratio after perfusion and capillary depletion?
• Is intact payload present in parenchyma, and in which cell populations?
• Does delivery produce target engagement at a tolerable systemic dose?
• How does performance compare with an unconjugated payload and a leading reference shuttle?
• Is transport saturable, receptor-dependent and preserved in NHP or human BBB models?

Safety

• What are the repeat-dose findings, anti-drug antibodies, complement and cytokine effects, and peripheral-organ exposures?
• Does receptor engagement alter iron, amino-acid, glucose or lipoprotein transport?
• For AAV, what are capsid immunity, shedding, integration, DRG pathology and redosing plans?
• For BBB opening, what are hemorrhage, edema, sterile inflammation and closure kinetics?

CMC

• What defines the drug substance and dose unit?
• Which critical quality attributes correlate with potency and biodistribution?
• Are loading, ligand density, particle size and release reproducible at intended scale?
• What comparability data support the clinical process, formulation and storage method?

IP and transaction

• Which claims cover the final construct, route, receptor and payload combination?
• Are rights encumbered by universities, existing partners, bankruptcy proceedings or change-of-control provisions?
• What is the remaining term, geographic coverage and likely design-around risk?
• Which datasets, cell lines, manufacturing methods and regulatory files transfer with the license or acquisition?

The search behind this report

Query: ("brain delivery"~4 OR "CNS delivery"~4 OR "blood brain barrier"~4) AND (nanoparticle OR liposome OR exosome OR "extracellular vesicle"~3 OR "viral vector"~3 OR "antibody shuttle"~3)

Filters: company type Therapeutic Biotech; patent publication date range January 2021 to December 2026. Sorting: most relevant. Result: 43 company profiles, all of which were evaluated.

Evaluation type: Key Technology. Each profile was assessed independently against its own recent research on delivery, blood-brain barrier, brain, CNS, nanoparticle, LNP, exosome or liposome, drawing on that company’s patents, publications, website, news, grants and clinical trials. The individual evaluations were then composed into this report.

Objective and boundaries

The report identifies targeted brain and CNS delivery technologies suitable for in-licensing, co-development, strategic investment or acquisition by pharmaceutical companies. It covers approaches that cross the blood-brain barrier, bypass it through cerebrospinal fluid or direct intracranial administration, exploit tumour-associated vascular disruption, or enable spatially controlled delivery with devices.

Companies whose primary activity is conventional CNS small-molecule discovery, diagnostics, ocular delivery, BBB modelling or non-CNS delivery were retained where they provide useful adjacent technology or validation, but were scored below platforms directly addressing targeted CNS delivery. Direct-CSF and intracranial platforms were evaluated alongside systemic BBB-crossing technologies, because they may offer superior near-term translation for selected payloads and diseases.

Public evidence was distinguished from company claims throughout. Patent grants demonstrate protectable subject matter, not biological performance; trial initiation demonstrates human exposure, not efficacy; and regulatory designations do not establish benefit. Transaction status is also material: Sangamo Therapeutics entered a Chapter 11 asset-sale process, Codiak Biosciences entered bankruptcy, Alcyone Therapeutics was acquired by Biogen, and Prevail Therapeutics and AskBio are already owned by large pharmaceutical companies.

The principal decision question is not merely whether a technology produces a brain-associated signal, but whether it can deliver an intact, pharmacologically active payload to the intended CNS compartment and cell type at a clinically acceptable dose and therapeutic index.

The delivery problem

The BBB is formed by specialised brain endothelial cells connected by tight junctions and supported by pericytes, astrocytes and extracellular matrix. It restricts paracellular movement, expresses active efflux systems and tightly regulates receptor- and transporter-mediated entry. Consequently, many antibodies, proteins, nucleic acids and nanoparticles have negligible brain-parenchymal exposure after systemic administration. A total-brain signal is not sufficient proof of delivery, because residual blood, endothelial retention, meninges, choroid plexus and CSF can be mistaken for parenchymal uptake.

Successful CNS delivery therefore requires evidence across a chain of events: systemic stability, BBB interaction or anatomical bypass, transcytosis or tissue distribution, cell entry, endosomal escape where required, payload release, target engagement and functional benefit. Each step may become payload-, species-, dose- and disease-dependent.